APS vs. REUN, NEPT, ATE, SBM, IMV, IOT, QPT, KNE, RVV, and PBS
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), Antibe Therapeutics (ATE), Sirona Biochem (SBM), IMV (IMV), Innovotech (IOT), Quest PharmaTech (QPT), Kane Biotech (KNE), Revive Therapeutics (RVV), and Pacgen Life Science Co. (PBS.V) (PBS). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs. Its Competitors
Reunion Neuroscience (TSE:REUN) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
In the previous week, Reunion Neuroscience's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.
Given Reunion Neuroscience's higher probable upside, equities analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences.
Reunion Neuroscience has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of -0.050988, indicating that its stock price is 105% less volatile than the S&P 500.
50.7% of Reunion Neuroscience shares are owned by institutional investors. Comparatively, 0.0% of Aptose Biosciences shares are owned by institutional investors. 34.4% of Reunion Neuroscience shares are owned by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Aptose Biosciences' return on equity of 1,017.48% beat Reunion Neuroscience's return on equity.
Reunion Neuroscience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Reunion Neuroscience, indicating that it is currently the more affordable of the two stocks.
Summary
Reunion Neuroscience beats Aptose Biosciences on 8 of the 12 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 9/12/2025 by MarketBeat.com Staff
Free APS Stock Alerts